jte-013 and Asthma

jte-013 has been researched along with Asthma* in 3 studies

Other Studies

3 other study(ies) available for jte-013 and Asthma

ArticleYear
Blockage of sphingosine-1-phosphate receptor 2 attenuates allergic asthma in mice.
    British journal of pharmacology, 2019, Volume: 176, Issue:7

    Sphingosine-1-phosphate 2 (S1P. Using an ovalbumin (OVA)-induced asthma model, the function of S1P. Eosinophil accumulation and elevated Th2 cytokine levels in bronchoalveolar lavage fluid and inflamed lung tissues were strongly inhibited by administration of JTE-013 before OVA sensitization, before OVA challenge, and before both events. In S1P. Pro-allergic functions of S1P

    Topics: Adoptive Transfer; Allergens; Animals; Anti-Asthmatic Agents; Asthma; Bronchoalveolar Lavage Fluid; Cytokines; Dendritic Cells; Eosinophils; Female; Lung; Mast Cells; Mice, Inbred BALB C; Mice, Knockout; Ovalbumin; Pyrazoles; Pyridines; Sphingosine-1-Phosphate Receptors

2019
Administration of JTE013 abrogates experimental asthma by regulating proinflammatory cytokine production from bronchial epithelial cells.
    Respiratory research, 2016, 11-09, Volume: 17, Issue:1

    Sphingosine-1-phosphate (S1P) is a bioactive phospholipid that acts as a signal transducer by binding to S1P receptors (S1PR) 1 to 5. The S1P/S1PRs pathway has been associated with remodeling and allergic inflammation in asthma, but the expression pattern of S1PR and its effects on non-immune cells have not been completely clarified. The aim of this study was to examine the contribution of the signaling of S1P and S1PRs expressed in airway epithelial cells (ECs) to asthma responses in mice.. Bronchial asthma was experimentally induced in BALB/c mice by ovalbumin (OVA) sensitization followed by an OVA inhalation challenge. The effects of S1PR antagonists on the development of asthma were analyzed 24 h after the OVA challenge.. Immunohistological analysis revealed S1PR1-3 expression on mouse airway ECs. Quantitative real-time polymerase chain reaction demonstrated that S1P greatly stimulated the induction of CCL3 and TIMP2 mRNA in human airway ECs, i.e., BEAS-2B cells, in a dose-dependent manner. Pretreatment with the S1PR2 antagonist JTE013 inhibited the CCL3 gene expression in BEAS-2B cells. Immunohistological analysis also showed that the expression level of CCL3 was attenuated by JTE013 in asthmatic mice. Furthermore, JTE013 as well as anti-CCL3 antibody attenuated allergic responses. Intratracheal administration of JTE013 also attenuated eosinophilic reactions in bronchoalveolar lavage fluids. S1P induced transcription factor NFκB activation, while JTE013 greatly reduced the NFκB activation.. JTE013 attenuated allergic airway reactions by regulating CCL3 production from bronchial ECs. The intratracheal administration of JTE013 may be a promising therapeutic strategy for bronchial asthma.

    Topics: Animals; Anti-Asthmatic Agents; Anti-Inflammatory Agents; Asthma; Bronchi; Chemokine CCL3; Cytokines; Disease Models, Animal; Epithelial Cells; Female; Inflammation Mediators; Lysophospholipids; Mice, Inbred BALB C; NF-kappa B; Ovalbumin; Pyrazoles; Pyridines; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Sphingosine-1-Phosphate Receptors; STAT3 Transcription Factor; Tissue Inhibitor of Metalloproteinase-2

2016
Downregulation of sphingosine-1-phosphate receptors in bronchial smooth muscle of mouse experimental asthma.
    Pharmacological research, 2010, Volume: 62, Issue:4

    To determine whether or not sphingosine-1-phosphate (S1P) is involved in the augmented bronchial smooth muscle (BSM) contractility, one of the causes of airway hyperresponsiveness in asthmatics, the effects of S1P on BSM tone were investigated in control and repeatedly antigen-challenged mice. Both in the control and antigen-challenged animals, S1P had no effect on basal tone of the isolated BSM tissues. However, in the BSMs pre-depolarized by 60mM K(+), S1P caused a significant increase in tension in the control mice. The S1P-mediated contraction was abolished by JTE-013, a selective S1P receptor 2 (S1PR2) antagonist, but not by W123, a selective S1PR1 antagonist, and BML-241, a selective S1PR3 antagonist. The S1P-mediated contraction observed in BSMs of the control mice was also inhibited by Y-27632, a Rho-kinase inhibitor, suggesting that the contraction is mediated via activations of S1PR2 and probably its downstream Rho-kinase. On the other hand, interestingly, the S1P-mediated contraction was not observed at all in BSMs of the repeatedly antigen-challenged mice. A marked and significant downregulation of mRNA for S1PR2 was also observed in BSM tissues of the diseased animals. In conclusion, S1P could augment the BSM contraction via activations of its JTE-013-sensitive receptor, probably S1PR2, and the RhoA/Rho-kinase signaling in normal mice. In BSMs of the repeatedly antigen-challenged mice, the expression level of S1PR2 was much decreased, resulting in a loss of the S1P-mediated contraction.

    Topics: Animals; Asthma; Bronchi; Down-Regulation; Lysophospholipids; Male; Mice; Mice, Inbred BALB C; Muscle Contraction; Muscle, Smooth; Pyrazoles; Pyridines; Receptors, Lysosphingolipid; rho-Associated Kinases; RNA, Messenger; Sphingosine; Sphingosine-1-Phosphate Receptors; Thiazolidines

2010